Skip to main content
Explore URMC

menu

Breast Cancer: Phase III study of hormone therapy with or without the study drug (Everolimus) in high risk hormone receptor positive & HER-2 negative breast cancer (S1207)

Research Question:
This study compares the use of hormones with a study drug (everolimus) to hormones alone after chemotherapy to see which will keep cancer from returning longer.

Basic Study Information

Purpose:
The purpose of this study is to see whether treatment with everolimus plus hormone treatment after chemotherapy will increase the time without your cancer returning. The current standard treatment after chemotherapy is hormone treatment alone. Everolimus is a drug currently approved for the treatment of patients with advanced or metastatic kidney cancer or breast cancer. It is considered investigational for non-metastatic breast cancer patients. In this study you will get hormone treatment with either everolimus or with placebo (a placebo is a tablet that looks like the active drug, but has no active drug in it). The combination of hormone-treatment and everolimus is experimental in patients with breast cancer.

Location: Cancer Center
Study Web URL:  http://clinicaltrials.gov/ct2/show/NCT01674140?term=S1207&rank=1
Study Reference #: CBRS-13015

Lead Researcher (Principal Investigator)

Lead Researcher: Michelle Shayne, MD

Study Contact Information

Study Coordinator: Kate Corcoran
Phone: (585) 275-7771
Email: Kathryn_Corcoran@URMC.Rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Breast Cancer

Return to Search